Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination
AssigneeBioNTach Ceil & Gene Therapies GmbH and TRON—Translationaie Onkologie an der Universitaismedizin der Johannes Gutenberg-univer
InventorsUgur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
Life of this patent
Estimating the term…
Abstract
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
Claims29
A method for stimulating an immune response to a target cell population or target tissue expressing an antigen in a mammal, the method comprising:
- (a) transfecting a T cell of the mammal with a first nucleic acid encoding a chimeric antigen receptor (CAR) targeted to the antigen, wherein transfecting the T cell is in vivo;
- and
- (b) administering a second nucleic acid encoding the antigen or a variant thereof, wherein the second nucleic acid is in vitro transcribed RNA disposed in liposomes, in a pharmaceutically acceptable carrier, diluent, buffer, preservative, or excipient.
A method of treating a mammal having a disease, disorder, or condition associated with expression or elevated expression of an antigen, the method comprising:
- (a) transfecting a T cell of the mammal with a first nucleic acid encoding a chimeric antigen receptor (CAR) targeted to the antigen, wherein transfecting the T cell is in vivo;
- and;
- and
- (b) administering a second nucleic acid encoding the antigen or a variant thereof, wherein the second nucleic acid is in vitro transcribed RNA disposed in liposomes, in a pharmaceutically acceptable carrier, diluent, buffer, preservative, or excipient.
Dependencies are inferred from the claim text.